KMPH VS BIOC Stock Comparison

PerformanceForecastSentimentTechnicalsEarningsProfitVolatilityDividendAnalyst Price Targets
PerformanceForecastSentimentTechnicalsEarningsProfitVolatilityDividendAnalyst Price Targets

Performance

KMPH
100/100

KMPH returned 1.93% in the last 12 months. Based on the other stocks in it's sector with an average return of -26.16%, it's performance is above average giving it a grade of 100 of 100.

BIOC
10/100

BIOC returned -98.16% in the last 12 months. Based on SPY's performance of -16.96%, its performance is below average giving it a score of 10 of 100.

Forecast

KMPH
85/100

5 analysts offer 12-month price forecasts for KMPH. Together, they have an average target of 10, the most optimistic forecast put KMPH at 10 within 12-months and the most pessimistic has KMPH at 10.

BIOC

"Forecast" not found for BIOC

Sentiment

KMPH
71/100

KMPH had a bullish sentiment score of 70.75% across Twitter and StockTwits over the last 12 months. It had an average of 74.19 posts, 109.25 comments, and 291.58 likes per day.

BIOC

"Sentiment" not found for BIOC

Technicals

KMPH
93/100

KMPH receieves a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.

BIOC
14/100

BIOC receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

KMPH
10/100

KMPH has missed earnings 9 times in the last 20 quarters.

BIOC
10/100

BIOC has missed earnings 9 times in the last 20 quarters.

Profit

KMPH
21/100

Out of the last 20 quarters, KMPH has had 4 profitable quarters and has increased their profits year over year on 3 of them.

BIOC
19/100

Out of the last 20 quarters, BIOC has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

KMPH
55/100

KMPH has had a higher than average amount of volatility over the last 12 months giving it a grade of 55 of 100.

BIOC
50/100

BIOC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

Dividend

KMPH
10/100

KMPH has not paid a dividend in the last 5 years.

BIOC

"Dividend" not found for BIOC

Analyst Price Targets

KMPH

"Analyst Price Targets" not found for KMPH

BIOC
75/100

3 analysts offer 12-month price targets for BIOC. Together, they have an average target of 0, the most optimistic target put BIOC at 0 within 12-months and the most pessimistic has BIOC at 0.

All score calculations are broken down here to help you make more informed investing decisions

KemPharm, Inc. Common Stock Summary

Nasdaq / KMPH
Healthcare
Biotechnology
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Biocept, Inc. Summary

Nasdaq / BIOC
Healthcare
Diagnostics & Research
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.